The Journal of Clinical Endocrinology & Metabolism · 2006 · 124 citations · 21 references
MedicineMaternal HealthObstetricsHigh-risk PregnancyMaternal-fetal MedicinePrenatal DiagnosisFetal PhysiologyIntrauterine Growth RestrictionMaternal-fetal PhysiologyPlacental PhysiologyPregnancyPregnancy PhysiologyBiomarkers Of PreeclampsiaCase-control Study DesignGestation PeriodIntrauterine Growth RetardationPreeclampsia PathophysiologyVascularization
CONTEXT: Vascular endothelial growth factor (VEGF) promotes placental vascularization, which is inadequate in preeclampsia and intrauterine growth retardation (IUGR). The soluble receptor of VEGF (sVEGFR-1), also known as soluble fms-like tyrosine kinase-1, is produced in the placenta and reduces VEGF activity. Therefore, elevated sVEGFR-1 could contribute to the development of preeclampsia and IUGR. OBJECTIVE: The objective of this study was to study maternal serum sVEGFR-1 concentration in early pregnancy ending in preeclampsia and IUGR. DESIGN: This was a case-control study. SETTING: This study was conducted at Helsinki University Central Hospital (Helsinki, Finland), a tertiary referral center. PATIENTS: Patients included 124 pregnant women, of whom 49 developed preeclampsia, 16 gave birth to IUGR infants without preeclampsia, and 59 remained normotensive and gave birth to normal-sized infants. Serum samples were collected at 12-15 and 16-20 gestational weeks. MAIN OUTCOME MEASURES: Serum sVEGFR-1 concentrations were determined by ELISA. RESULTS: Women with subsequent preeclampsia had higher [median; interquartile range (IQR)] concentrations of sVEGFR-1 at 16-20 wk gestation (436 and 282-699 ng/liter; P = 0.005) than the controls (296 and 184-508 ng/liter). The conclusion was the same if women with mild (340 and 285-750 ng/liter; P = 0.043) or severe (497 and 235-699 ng/liter; P = 0.022) preeclampsia were analyzed separately. An elevated sVEGFR-1 concentration at 16-20 wk gestation is associated with an increased risk of preeclampsia but not of isolated IUGR. Soluble VEGFR-1 concentration decreased by 15% from the first to the second sampling in the controls but not in women with preeclampsia or IUGR. CONCLUSION: Elevated sVEGFR-1 concentrations at 16-20 wk gestation precede the clinical manifestations of preeclampsia. By neutralizing VEGF, sVEGFR-1 may contribute to inadequate placental vascularization.
21
Sharon E. Maynard, Jiang-Yong Min, Jaime R. Merchan et al. · Journal of Clinical Investigation · 2003 · 4K citations · Full text
Vascular endothelial growth factor (VEGF) and its receptors
Gera Neufeld, Tzafra Cohen, Stela Gengrinovitch et al. · The FASEB Journal · 1999 · 3.5K citations
Medicine, Cell Biology, Oncology +17
Circulating angiogenic factors and the risk of preeclampsia*
Obstetrics and Gynecology · 2004 · 2.6K citations
Medicine, Gynecology, Obstetrics +14